Arexis Overview

  • Founded
  • 1999
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $10.1M
Latest Deal Amount

Arexis General Information

Description

Operator of a pharmaceutical company intended to develop metabolic and inflammatory disease therapeutics. The company's research is biology-driven with proprietary technology and a focus on the development of pharmaceuticals for the treatment of lipid malabsorption, diabetes, atopic dermatitis (inflammatory skin disease) and rheumatoid arthritis, enabling doctors with novel therapies to easily treat patients.

Contact Information

Website
www.arexis.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Acquirer
Primary Office
  • Arvid Wallgrens Backe
  • 413 46 Gothenburg
  • Sweden
+46 031-749 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arexis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 22-Aug-2005 $10.1M 000.00 000.00 Completed Clinical Trials - General
3. Early Stage VC 01-Jul-2003 00.000 000.00 Completed Startup
2. Early Stage VC 30-May-2001 $4.64M $4.64M Completed Startup
1. Early Stage VC Completed Startup
To view Arexis’s complete valuation and funding history, request access »

Arexis Patents

Arexis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120156235-A1 Antibodies against and methods for producing vaccines for respiratory syncytial virus Granted 02-Feb-2009 0000000000 0
US-8852608-B2 Antibodies against and methods for producing vaccines for respiratory syncytial virus Active 02-Feb-2009 0000000000 0
US-20150125479-A1 Antibodies against and methods for producing vaccines for respiratory syncytial virus Granted 02-Feb-2009 0000000000
US-9499590-B2 Antibodies against and methods for producing vaccines for respiratory syncytial virus Active 02-Feb-2009 0000000000
US-20100278852-A1 Antibodies against and methods for producing vaccines for respiratory syncytial virus Granted 21-Sep-2004 A61K39/155 0

Arexis Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3i Group PE/Buyout Minority 000 0000 000000 0
Industrifonden Venture Capital Minority 000 0000 000000 0
InnovationsKapital Venture Capital Minority 000 0000 000000 0
Kreos Capital Lender/Debt Provider Minority 000 0000 000000 0
Skandinaviska Enskilda Banken Investment Bank Minority 000 0000 000000 0
To view Arexis’s complete investors history, request access »